JPMorgan Chase & Co. Has $39.78 Million Stock Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

JPMorgan Chase & Co. decreased its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 21.6% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 500,723 shares of the company’s stock after selling 138,035 shares during the period. JPMorgan Chase & Co. owned about 0.06% of Dr. Reddy’s Laboratories worth $39,782,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its position in shares of Dr. Reddy’s Laboratories by 43.2% in the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after purchasing an additional 137 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Dr. Reddy’s Laboratories during the 3rd quarter worth approximately $60,000. Van ECK Associates Corp raised its position in shares of Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after purchasing an additional 322 shares during the period. GAMMA Investing LLC lifted its stake in shares of Dr. Reddy’s Laboratories by 83.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,447 shares of the company’s stock worth $115,000 after buying an additional 657 shares during the last quarter. Finally, Glenmede Trust Co. NA bought a new stake in shares of Dr. Reddy’s Laboratories during the 3rd quarter worth about $207,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Down 1.5 %

Shares of RDY opened at $15.44 on Monday. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 12 month low of $13.43 and a 12 month high of $16.89. The firm’s 50 day moving average is $14.78 and its 200-day moving average is $15.51. The stock has a market capitalization of $12.89 billion, a PE ratio of 24.66 and a beta of 0.53.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Barclays reduced their price objective on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Finally, Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.